HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


Significance of Vitamin D Status in Obese Adolescents- A Pilot Study to Examine the Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

Signup
Browse Studies

City:   Rochester
State:   Minnesota
Zip Code:   55905
Conditions:   Obesity
Purpose:   The prevalence of obesity has reached epidemic proportions nationally as well as internationally. Currently, 16 % of American adolescents are obese. In adults, obesity is a risk factor for vitamin D insufficiency and up to 80% of obese adults have been noted to vitamin D insufficient. In adults, low vitamin D status appears to be associated with the development of type 2 diabetes and metabolic syndrome. There is little information on the prevalence of vitamin D insufficiency and its implications in obese adolescents. Additionally, it is unknown whether treatment of vitamin D insufficiency in adolescents might result in improvement in insulin resistance, lipids and cardiovascular risk markers. We hypothesize that vitamin D insufficiency correlates positively with insulin resistance and cardiovascular risk in obese adolescents and that vitamin D3 supplementation improves insulin resistance and cardiovascular risk factors in this population. The purpose of the study is to determine the impact of vitamin D3 supplementation on various parameters of insulin secretion, insulin action, lipids and C-reactive protein in obese adolescents.
Study Summary:   The problem of childhood obesity has reached epidemic proportions both nationally and internationally. The prevalence of obesity has tripled in the last three decades and currently 16 % of American adolescents are obese. Nearly 30% of obese adolescents demonstrate a metabolic syndrome characterized by insulin resistance and dyslipidemia. These abnormalities lead to the development of type 2 diabetes mellitus and to increased cardiovascular morbidity and mortality. Obesity is a well-known risk factor for vitamin D insufficiency and up to 80% of obese adults have been found to be insufficient in vitamin D. Observational studies in adults have shown consistent associations between low vitamin D status and prevalence of type 2 diabetes mellitus and metabolic syndrome. There is paucity of data on the prevalence of vitamin D insufficiency and its implications in obese adolescents. It is also not known whether treatment of vitamin D insufficiency in children or adults might result in improvement in insulin resistance and cardiovascular risk factors. Hypotheses: We hypothesize that vitamin D insufficiency correlates positively with insulin resistance and cardiovascular risk in obese adolescents and that vitamin D3 supplementation decreases insulin resistance and cardiovascular risk factors in this population. Objectives: 1. Determine if there is any correlation between serum 25(OH)D levels and HOMA-IR, HDL cholesterol and C-reactive protein, in obese adolescents. 2. Study the impact of vitamin D3 supplementation on various parameters reflecting insulin action, secretion, lipids and C-reactive protein in obese adolescents.
Criteria:   Inclusion Criteria: 1. Age between 12-18 years 2. BMI is at or greater than the 95th percentile for age and gender Exclusion Criteria: 1. Subjects with 25 (OH)- D levels >100 ng/mL 2. Serum calcium >10.8 mg/dL 3. Current cancer 4. Those taking a multivitamin supplementation 5. Hepatic or renal disorders 6. Type 1 or type 2 diabetes mellitus. 7. Those receiving insulin, metformin or oral hypoglycemic medications - Use of glucocorticoids and anti-seizure medications in the previous 6 months - Malabsorption syndromes such as celiac disease
NCT ID:   NCT00858247
Primary Contact:   Principal Investigator
Seema Kumar, M.D.
Mayo Clinic

Backup Contact:   N/A
Location Contact:   Rochester, Minnesota 55905
United States



There is no listed contact information for this specific location.

Site Status: N/A

Data Source:   ClinicalTrials.gov
Date Processed:   May 22, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


  • NEARBY STUDIES

Within 25 Miles

Multiple Myeloma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma - Rochester MN

Uncontrolled Angina (Adult Stem Cell Research) - Rochester MN

Within 50 Miles

Within 100 Miles

Dry Eye - Stillwater MN

Irritable Bowel Syndrome (with diarrhea) - Chaska MN

Multiple Sclerosis - Minneapolis MN

Obsessive Compulsive Disorder (OCD) - Minneapolis MN

Uncontrolled Angina (Adult Stem Cell Research) - Minneapolis MN

COPD (Emphysema and Chronic Bronchitis) - Minneapolis MN

COPD (Emphysema and Chronic Bronchitis) - Minneapolis MN

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.